Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + tolecimab in advanced driver gene-negative NSCLC after failure of first-line immunotherapy
ChiCTR2500099426Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and tolecimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
sintilimabtolecimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500099426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099426.